What this Trial Is About

Researchers are evaluating the effects of angiotensin receptor blockers (ARBs) on patients with mild-to-moderate aortic stenosis, a condition where the aortic valve narrows and affects heart function. This phase 4 randomized controlled trial aims to determine if ARBs can slow the progression of valve narrowing and reduce remodeling or dysfunction of the left ventricle. The study builds on evidence suggesting that the renin-angiotensin system plays a role in worsening valve stenosis and heart muscle fibrosis. Participants will be randomly assigned to receive either angiotensin receptor blockers or a placebo for a period of two years. The treatments will be administered continuously during this time to evaluate their impact on the progression of aortic stenosis and heart structure changes. Both groups will be closely monitored throughout the study period. During the trial, researchers will assess changes in the anatomical progression of aortic stenosis from the start to the end of the two-year treatment. Participants will undergo regular evaluations to monitor heart function and valve condition. Safety and adherence will also be tracked to ensure participant well-being and accurate measurement of treatment effects over the study duration.

Angiotensin Receptor Blockers in Aortic Stenosis